References
Gleich GJ. historical overview and perspective on the role of the eosinophil in health and disease. In: Rosenberg H, Lee JJ, eds. Eosinophils in Health and Disease. San Diego, CA: Academic Press; 2012:1-11.
- Total eosinophil counts in the management of bronchial asthma.N Engl J Med. 1975; 292: 1152-1155
- Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum.Lancet. 1958; 2: 1245-1247
- The evolution of sputum cytometry to assess bronchitis.Can Respir J. 2013; 20: 415-416
- Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice.Can Respir J. 2011; 18: 144-148
- Biomarkers predicting response to corticosteroid therapy in asthma.Treat Respir Med. 2005; 4: 309-316
- The demise of anti IL-5 for asthma, or not.Am J Respir Crit Care Med. 2007; 176: 1059-1060
- Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.N Engl J Med. 2009; 360: 985-993
- Mepolizumab and exacerbations of refractory eosinophilic asthma.N Engl J Med. 2009; 360: 973-984
- Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.Am J Respir Crit Care Med. 2011; 184: 1125-1132
- External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma.Thorax. 2015; 70: 115-120
- Blood or sputum eosinophils to guide asthma therapy?.Lancet Respir Med. 2015; 3: 824-825
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.Lancet. 2012; 380: 651-659
- Mepolizumab treatment in patients with severe eosinophilic asthma.N Engl J Med. 2014; 371: 1198-1207
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.Lancet Respir Med. 2015; 3: 355-366
- Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.Lancet Respir Med. 2014; 2: 879-890
- Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia.J Allergy Clin Immunol. 2016; 137: 75-86
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.Lancet Respir Med. 2016; 4: 549-556
- Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.Clin Exp Allergy. 2016; 46: 793-802
Article Info
Footnotes
FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: P. N. is supported by the Frederick E. Hargreave Teva Innovation Chair in Airway Diseases. P. M. O. and P. N. are supported by the AllerGen National Centre of Excellence. Both P. N. and P. M. O. have held grants-in-aid from GSK for the investigation of mepolizumab. P. N. also reports grants from AstraZeneca, Sanofi, Teva, Novartis, Boehringer Ingelheim, and Roche, and honoraria for consultancies and lectures from Sanofi, Roche, Teva, AstraZeneca, Knopp, and Daiichi Sankyo. P. M. O. also reports grants and personal fees from AstraZeneca; personal fees from Chiesi, Boehringer Ingelheim, GSK, MedImmune, Merck, Takeda, and Abbott; and grants from Amgen, Novartis, Genentech, Axican, and Alakos outside of the submitted work.
